Supernus Q4 rev $164.3M, Qelbree +97% YoY; FY23 GAAP op loss $5.3M, non-GAAP op earnings $125.1M

SUPERNUS PHARMACEUTICALS, INC.

2024-FY EPS reported $0.02 revenue$607,521,000

Q4 2023 total revenues $164.3M (GAAP); full year 2023 total revenues $607.5M, down 9% YoY.
Qelbree net sales Q4 $46.4M (+97% YoY), full year $140.2M (+129%); GOCOVRI Q4 $32.0M (+10%), full year $119.6M (+15%).
Full year 2023 GAAP operating loss $(5.3)M; non-GAAP operating earnings $125.1M. GAAP net earnings $1.3M ($0.02 diluted EPS).
FY2024 guidance: total revenues $580-$620M; non-GAAP operating earnings $80-$110M; expects generic erosion of Trokendi XR/Oxtellar XR from Sep 2024.
Pipeline: SPN-830 PDUFA April 5, 2024; Phase IIb SPN-820 data H1 2025; interim Phase IIa SPN-817 data May 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. reported Full year 2023 results: revenue Total revenues (GAAP) of $607.5 million.

Period: Full year 2023
Revenue: Total revenues (GAAP) of $607.5 million
Result: reported results

Exact text from the filing

For the full year ended December 31, 2023, total revenues and total net product sales were $607.5 million and $573.9 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. reported Fourth quarter 2023 results: revenue Total revenues (GAAP) of $164.3 million.

Period: Fourth quarter 2023
Revenue: Total revenues (GAAP) of $164.3 million
Result: reported results

Exact text from the filing

For the three months ended December 31, 2023, total revenues and total net product sales (GAAP) were $164.3 million and $156.0 million, respectively

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.